3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
6
Phase 3
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Uterine Cervical Dysplasia
2
Uterine Cervical Neoplasms
1
Papillomavirus Infections
1
Cervical Intraepithelial Neoplasia Grade 2/3
1
Interventions
human papillomavirus vaccine, L1 type 16, 18
22
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
15
Papillomavirus Vaccines
9
Vaccines
6
Blood Specimen Collection
4
Watchful Waiting
2
Vaccines, Synthetic
2
Light Coagulation
2
Hepatitis A Vaccines
2
Engerix-B
2
lime
1
halofantrine
1
Sodium Chloride
1
Radiotherapy, Intensity-Modulated
1
Pentetic Acid
1
Olive Oil
1
Observation
1
Measles-Mumps-Rubella Vaccine
1
Laser Therapy
1
Injections
1
Imiquimod
1
Human Papillomavirus DNA Tests
1
Fluorouracil
1
Diphtheria-Tetanus-acellular Pertussis Vaccines
1
DTPa-HBV-IPV combined vaccine
1
Colposcopy
1
Clinical Protocols
1
Cisplatin
1
Circumcision, Male
1
Chorionic Villi Sampling
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Papillomavirus Infections
×
Colposcopy
×
Clear all
NCT04794660
2024-03-13
CESTA
International Agency for Research on Cancer
Phase 3
Unknown
1,500 enrolled